Sartorius
We're hiring — explore open roles below and apply in a few clicks.
Location
Headquarters: Göttingen, Niedersachsen, Germany, Europe
Region: Niedersachsen
Country: DE
Continent: Europe
About
Sartorius is a global life sciences company offering solutions for the biopharmaceutical industry and laboratories, spanning drug discovery and development to production platforms for biomanufacturing. The company provides laboratory equipment, consumables, and process analytics across bioprocessing, cell culture, and applied life sciences. Headquartered in Göttingen, Germany, Sartorius serves customers worldwide with a focus on enabling faster, more reliable bioprocess and research workflows.
Sartorius AG provides laboratory instruments and bioprocessing technologies for the life sciences sector. Its Bioprocess Solutions division supplies single-use systems and filtration for biopharmaceutical manufacturing, while the Laboratory Products division offers analytical balances and pipettes. The company serves pharmaceutical firms and research institutions globally.
Sartorius AG
1870
for_profit
active
Industries
Primary Industry: Manufacturing
Categories
Funding & Financials
Public Company
$3.21B
over-1b
ipo
XETR:SRT3
fra
Founders
Florence Kurth
Florenz Sartorius
Leadership
Mario Becker — Director Marketing Fermentation Technologies North America
Maurice Phelan — President, North America
Thomas Duensing — Head of BioAnalytics Product Development
Torsten G. Mueller — Chief Information Officer and Managing Director
Sean Tasdemir — Key Account Manager
Cornelia Lindner — Team Leader Operations
Miriam Monge — Global Director of Marketing Sartorius Integrated Solutions
Technology Stack
Products
Bioprocess Solutions: Provides equipment and services for the development and production of biopharmaceuticals, including filtration, fermentation, and purification technologies.
Lab Products & Services: Offers laboratory instruments and consumables for research and quality control in pharmaceutical and biotechnological applications.
Funding rounds
Post Ipo Debt · $3.21B · (2023-09-07)
IPO · (1990-07-10)
